HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EEOC v. Dial

This article was originally published in The Rose Sheet

Executive Summary

Sexual harassment trial moves forward after Chicago Court of Appeals rejects Dial's interim appeal on a motion of summary judgement Feb. 12. Lawsuit filed in May 1999 by Equal Employment Opportunity Commission alleges approximately 90 female workers at Dial's Aurora, Ill. soap manufacturing facility were exposed to verbal abuse, pornography and assault. Trial date is not yet set, according to EEOC. Chicago Federal Court denied Dial's motion of summary judgment in August (1"The Rose Sheet" Aug. 27, 2001, In Brief)...

You may also be interested in...



EEOC v. Dial

Sexual harassment case against Dial will proceed after Chicago federal court denies company's motion for summary judgement Aug. 9. Lawsuit filed in May 1999 by Equal Employment Opportunity Commission alleges approximately 90 female workers at Dial's Aurora, Ill. manufacturing facility were exposed to verbal abuse, pornography and assault while the company's response was "malicious, reckless and ineffective." Dial's liability in the case could exceed $25 mil., according to EEOC. Dial maintains, "There is no finding in this decision that Dial violated the law in any manner"

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel